The Hong Kong University of Science and Technology (Guangzhou) (HKUST-GZ) is a world-class research university established in 2022 as a joint venture between HKUST and Guangzhou University. Operating under a 'Unified HKUST, Complementary Campuses' framework, it serves as a major hub for interdisciplinary research and industrial transformation in the Greater Bay Area (GBA). The institution is specifically designed to bridge the gap between fundamental academic research and commercial application, with a heavy emphasis on biotechnology, artificial intelligence, and advanced materials.
In the pharmaceutical and biotech sectors, HKUST-GZ operates through its Systems Hub and the Bioscience and Biomedical Engineering Thrust (BSBE). It hosts the Biosciences Central Research Facility (BioCRF), which provides high-throughput screening, genomics, and proteomics capabilities. The university is a primary engine for biotech innovation in the region, managing significant venture funds and maintaining strategic R&D partnerships with global pharmaceutical leaders to accelerate drug discovery and medical device development.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biomedical Engineering & Drug Discovery
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$500M-$1B
Founded:2022
Ownership:government
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$350M
Investors:Guangzhou Municipal Government, Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC), Gobi Partners, Hong Kong Investment Corporation (HKIC), Guangzhou Industry Investment Holding Group
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Ophthalmic ultrasound delivery)
Modalities:Small molecule, mAb, Cell therapy, Drug Delivery Systems (Ultrasound), Biomaterials, AI-driven Diagnostics
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:The Hong Kong University of Science and Technology (HKUST)
Subsidiaries:HKUST R&D Corporation Limited (Guangzhou), Fok Ying Tung Research Institute (FYTRI), Opharmic Technology (Spin-off), Yuanhuo Technology (Spin-off)
Key Partnerships:AstraZeneca (MoU for AI in life sciences and rare diseases), Luye Pharma (CNS and neuroscience research), Boan Biotech (Novel anticancer drug development), Sun Yat-sen University First Affiliated Hospital (Clinical education and research), Guangzhou Pharmaceutical Holdings Limited (Anticancer treatments)
COMPETITION
Position:Leader
Competitors:Tsinghua University (Shenzhen), Peking University (Shenzhen), Chinese University of Hong Kong (Shenzhen), WuXi AppTec (in R&D services)
LEADERSHIP
Key Executives:
Lionel M. Ni - Founding President
Nancy Ip - President (HKUST) & Key Researcher
Robert Zhong Qi - Acting Dean of Systems Hub
Hui Xiong - AVP (Knowledge Transfer)
Scientific Founders:Prof. Nancy Ip, Prof. Robert Zhong Qi, Prof. Weijia Wen
Board Members:Prof. Harry Shum (Council Chairman), Ms. Edith Shih (RIF Chairperson), Prof. Tim Cheng (VP Research & Development)
LINKS
Website:hkust-gz.edu.cn
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hong Kong University of Science and Technology (Guangzhou). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.